Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

Sanofi reception

Sanofi’s oral therapy Aubagio approved in the EU for paediatric MS patients

EC approval comes a few weeks after the FDA rejected Aubagio in the same patient population

- PMLiVE

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

By Henry Skinner, Chief Executive Officer of the AMR Action Fund

- PMLiVE

Court rules on AZ and EU’s COVID-19 vaccine dispute

The Court in Brussels has ordered AZ to deliver a total of 80.2 million doses to the EU by 27 September 2021

- PMLiVE

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has initiated the late-stage study based on positive results from the phase 2 LILAC study

- PMLiVE

US announces $3bn funding boost for antiviral COVID-19 treatments

Funding will go towards the discovery, development and manufacturing of antiviral medicines

- PMLiVE

‘Funny’, ha ha: how neurodiverse comedy can help us understand each other

Ever since Hans Asperger showed cartoons to his ‘little professors’ and they didn’t laugh, it was believed that people with autism lacked a sense of humour. Today, a new wave...

11 London

- PMLiVE

BMS and Eisai to collaborate in deal worth up to $3.1bn

The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers

Staying in the loop – six principles for impactful integrated communications

In a digitalised world, accelerated by the COVID-19 pandemic, pharmaceutical companies must work smarter to engage busy external stakeholders with endless content at their fingertipsIn this month’s edition of PME James...

Lucid Group Communications Limited

- PMLiVE

How early-stage clinical research is facilitating the new wave of personalised medicines

By Jorg Taubel

- PMLiVE

Kite partners with Shoreline Biosciences to develop allogeneic cell therapies

The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront payment

- PMLiVE

Fishawack Health acquires digital marketing agency closerlook

closerlook leverages AI and data analytics to develop omnichannel strategies, creative and digital media solutions for life sciences brands

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links